DHI vs premade slits evidence is easy to misread because the terms do not consistently describe opposite procedures. “DHI” is commonly used for a recipient-area placement workflow involving a Choi-style implanter, while “premade slits” describes the creation of recipient openings before grafts are inserted. An implanter can be used after premade sites have been created. Conversely, a sharp implanter can create an opening and place a graft in a closely linked sequence. The names alone do not reveal the whole operation.
For anyone comparing DHI vs premade slits evidence, the useful question is not which label sounds more advanced. It is which steps are proposed: how follicles are harvested, when recipient sites are made, how grafts are loaded and placed, how angle and spacing are planned, who performs each task, and how tissue is protected across the entire session. The available studies describe useful technical workflows, but they rarely provide the kind of large, controlled, like-for-like comparison needed to claim that one label reliably produces a better result for every patient.
Why the comparison starts with four separate decisions
A hair transplant is a chain of decisions rather than a single device choice. Donor harvesting concerns how follicular units are removed from the donor scalp. Recipient-site creation concerns the openings that will receive those units. Graft loading and placement concern the instruments, handling and sequence used to introduce a prepared graft. Finally, design concerns the distribution, graft selection, direction, angle and depth appropriate for the particular region. A procedure can use FUE harvesting, premade recipient sites and implanter placement in the same case.
This is why DHI should not be treated as the opposite of FUE, nor as a complete description of recipient-site design. The earlier Choi implanter and DHI evidence review explains the historical device and its placement logic. The DHI hair-transplant operation overview gives practical procedure context. Neither label answers whether sites will be made in advance, whether a sharp pen will enter untreated scalp, or whether a pen will be used to deliver grafts into openings made by another instrument.
Separating the steps is also a safeguard against misleading claims. An implanter does not create extra donor hair. A preformed site does not decide the future pattern of androgenetic alopecia. Neither method identifies an unstable donor area, replaces diagnosis or guarantees a particular density. A responsible consultation should describe the proposed sequence in plain language rather than compressing several independent decisions into a brand-like acronym.
What “premade slits” actually means
In a premade-site workflow, the clinician maps and creates recipient openings before the grafts are inserted. The openings may be made with blades or needles, and grafts may subsequently be placed with forceps or an implanter. That ordering can allow the overall recipient design to be viewed before placement begins: the clinician can assess transitions between zones, the intended distribution of single- and multi-hair grafts, and the changing direction of native hair. It also requires careful coordination, because prepared grafts must still be handled, stored and placed appropriately.
Premade does not mean mechanically identical. The shape, width, depth, orientation and spacing of sites must fit the grafts and the recipient tissue. The recipient-area review by Marwah and Mysore presents premade slits, stick-and-place and implanter placement as distinct technical options with different practical strengths and constraints. It does not establish a universal winner. The more focused research on recipient-site angle and direction explains why the same opening geometry cannot be copied from a soft frontal transition to a temple point, mid-scalp or crown whorl.
Patient-facing language should remain cautious here. A preformed site may give a surgeon a way to plan an area in advance; it does not make every team’s placement atraumatic or every graft secure. A site that is poorly matched to the graft or local tissue can make insertion difficult. Sites that are too close, too deep or poorly oriented can create practical and aesthetic problems. In contrast, a carefully performed premade-site procedure can be a highly controlled option. The quality of the design and execution matters more than the fact that sites were made first.
What implanters and DHI workflows change—and what they do not
A Choi-style implanter is a needle-based placement instrument. A prepared follicular-unit graft is loaded into the device, then the operator introduces it at a planned position and uses a plunger or introducer to leave it at an intended depth. In a sharp-needle version, creation of an opening and delivery of the graft can be closely associated. In other workflows, an implanter is used to deliver grafts into recipient sites that have already been made. The instrument is therefore part of the placement stage, not a substitute for donor-harvest assessment or recipient design.
Implanters may have practical value when a team has the training and workflow to load grafts accurately, select suitable instrument sizes and place them without excessive force. They may be useful in work among existing hair or in areas where fine control of placement is important. Those possibilities are not outcome guarantees. Grafts still have to be extracted without avoidable injury, kept hydrated, loaded without crushing, placed at an appropriate angle and depth, and protected after the procedure. A pen cannot correct a weak donor reserve, an unsuitable hairline or a crowded recipient plan.
The surgical literature also makes clear that implanter use entails its own demands. Loading requires trained assistance and coordination; the instrument must suit the graft; and placement is still operator dependent. “No touch” is therefore not a scientific synonym for “no risk.” An implanter may reduce direct forceps contact during part of final insertion in a given workflow, but it does not mean a graft has never been handled or that its later growth is assured. The broad graft survival, ischemia, storage and handling review explains why preservation depends on the whole chain of care.
What the named implanter studies actually compare
The most important corrective to a simple DHI-versus-slits story comes from the 2019 observational series by Bansal and colleagues. It described 104 FUE patients in whom implanters were used in premade recipient sites while extraction and placement were coordinated. In other words, the paper documents a combined workflow rather than treating an implanter and premade sites as mutually exclusive alternatives. The authors reported practical observations, but the study did not objectively measure regrowth and did not include a direct comparison group. It can inform a discussion of workflow; it cannot prove that implanters beat forceps placement, or that DHI beats premade sites.
A 2013 29-patient series titled Direct Hair Transplantation also illustrates why terminology needs unpacking. It described a coordinated sequence in which recipient sites were made before extraction and placement proceeded in close succession. That strategy may be intended to organise graft time outside the body, but it was a case series, not a randomised comparison of placement instruments. It should not be converted into a generic promise that any procedure advertised as direct implantation delivers higher survival or faster recovery.
Earlier device-specific evidence is similarly narrower than marketing summaries suggest. A 2001 KNU-implanter study in 11 patients compared one-hair and two-hair follicular-unit grafts in marked recipient templates and reported follow-up hair-count survival. It contributes useful information about a defined device and graft configuration. It was not a broad head-to-head test of DHI against forceps in premade slits, and its figures cannot be applied as a universal patient-level growth forecast.
Technical reviews can clarify mechanisms and workflow, but they are not the same as comparative outcome trials. The 2021 hair-transplant practice guidelines explicitly note that controlled data are unavailable for many techniques and protocols in routine use. The practical conclusion is not that implanters are unproven or that premade sites are outdated. It is that a claim of superiority must be no broader than the evidence supporting it.
Recipient capacity, direction and spacing do not disappear with a pen
Whether sites are made first or are coupled to implanter insertion, the recipient scalp is not a blank surface. It contains native hair, variable tissue thickness and blood supply, and regional patterns that need to be respected. A frontal leading edge usually calls for a different graft mix and exit pattern from a crown. A temple requires a different visual flow from the mid-scalp. The clinician must decide how the grafts will be arranged before a placement instrument can execute that plan.
Atodaria and colleagues’ recipient-slit design article makes a useful anatomical point: the volume and depth of the recipient incision, as well as its shape, influence the amount of tissue affected. Its recommendations are reasoned technical guidance, not a universal density formula. A method cannot make very aggressive packing automatically safe. The related review of dense packing, graft spacing and density claims explains why recipient capacity depends on graft size, tissue characteristics, pre-existing hair, site design, distribution and the wider surgical context.
That is why neither a “maximum-density DHI” claim nor a blanket “premade slits are safer” claim should settle a decision. Excessive pressure, repeated manipulation, mismatched site size, poor depth control or a plan that ignores long-term donor reserve can be harmful in any workflow. Conversely, a careful operator can use different placement methods thoughtfully in different zones. The method should be justified by the recipient map and the team’s actual competence, not by a promise that one instrument eliminates biological trade-offs.
Handling, timing and team roles are part of the comparison
Graft protection begins before placement. Follicular units are vulnerable to unnecessary traction, drying, temperature changes, crushing and avoidable delay while outside the body. A coordinated implanter workflow may be designed to reduce some steps or organise the interval between extraction and placement. A premade-site workflow may allow a team to plan the recipient field while other members manage graft preparation. Neither description establishes quality without details of hydration, storage, loading, communication and graft inspection.
The responsible clinician should be able to explain who evaluates donor density and miniaturisation, who designs the recipient pattern, who creates recipient sites, who extracts grafts, who loads an implanter or uses forceps, and who is supervising the operation. The ISHRS FUE Clinical Practice Guidelines and the 2021 practice guidelines both support clear physician responsibility for surgical planning and appropriately trained personnel. A patient should not have to infer medical responsibility from a device name or from a coordinator’s sales description.
There is also a practical trade-off between parallel work and control. Multiple trained staff may place grafts in a premade-site workflow, whereas an implanter workflow can be more dependent on the trained person placing each unit. Neither staffing pattern is automatically better. The relevant safeguards are whether roles are transparent, the workflow is appropriate to the session size, grafts are inspected and protected, and the plan can change if donor or recipient conditions make the original target inappropriate.
Questions that turn a label into an accountable plan
Before agreeing to a DHI-labelled procedure, ask whether recipient sites will be premade, created with a sharp implanter, or handled through a combination of methods. Ask why that sequence is proposed for your recipient area, whether it changes across the hairline and crown, and which clinician is responsible for design and site creation. A credible explanation makes room for uncertainty rather than stating that a pen is always less traumatic or always denser.
Ask separately about the donor side: which extraction method is proposed, how the donor area was assessed, how early grafts are checked, and what would lead the team to reduce or modify the session. Then ask about graft protection: how units are hydrated and stored, who loads them, how damaged grafts are recognised and how staff coordinate the timing of extraction and placement. The patient-friendly DHI hair-transplant guide provides practical consultation context; a discussion that needs a neutral service overview can also use the site’s DHI service-context page. Neither page replaces individual medical assessment.
Finally, ask what outcome a clinic means by “better.” Does it refer to a particular handling step, a shorter stage of a procedure, photographs, an internal audit or a controlled comparative study? Request that the answer distinguish hypothesis from measured evidence. A team that can explain why a smaller, staged or different approach may be safer is providing more meaningful information than one that promises a fixed density from a named device. For broad surgical context, see the hair-transplant operation overview.
Limits of the evidence
The implanter literature includes original device reports, small follow-up studies, technical reviews and observational series. Devices, needle dimensions, graft types, donor methods, recipient zones, staff roles and outcome definitions vary substantially. Many publications describe feasibility or expert technique rather than comparing implanter placement with forceps placement in otherwise identical premade sites. Study results may be influenced by operator experience, patient selection, photography methods and follow-up duration.
Mechanistic reasoning is valuable but must not be overstated. It is plausible that careful handling, fitting a graft to its site and an efficient workflow can protect grafts. It does not follow that a specific pen guarantees less trauma, less bleeding, faster healing, higher survival or a universal density advantage. Recipient-site research also contains expert recommendations that must be tailored to individual scalp and graft characteristics. Online readers cannot determine a suitable surgical sequence from a density target or device label alone.
Conclusion
DHI vs premade slits evidence does not support a simple winner. The most directly relevant implanter series may combine implanters with premade recipient sites, demonstrating that the comparison is often a false either-or choice. The strongest patient question is therefore: which donor, site-creation, handling and placement steps will be used in this particular plan, who is accountable for them, and what evidence supports the claimed advantage? DHI can be a legitimate placement workflow and premade sites can be a legitimate planning strategy. Neither is a medical outcome guarantee.
The related FUE, DHI and Sapphire technique-label evidence review places this recipient-side comparison within the full procedure, separating donor harvesting, site creation and placement rather than treating three labels as three mutually exclusive operations.
